aKlotho is a multifunctional protein highly expressed in the kidney. Soluble aKlotho is released through cleavage of the extracellular domain from membrane aKlotho by secretases to function as an endocrine/paracrine substance. The role of the kidney in circulating aKlotho production and handling is incompletely understood, however. Here, we found higher aKlotho concentration in suprarenal compared with infrarenal inferior vena cava in both rats and humans. In rats, serum aKlotho concentration dropped precipitously after bilateral nephrectomy or upon treatment with inhibitors of aKlotho extracellular domain shedding. Furthermore, the serum half-life of exogenous aKlotho in anephric rats was four-to five-fold longer than that in normal rats, and exogenously injected labeled recombinant aKlotho was detected in the kidney and in urine of rats. Both in vivo (micropuncture) and in vitro (proximal tubule cell line) studies showed that aKlotho traffics from the basal to the apical side of the proximal tubule via transcytosis. Thus, we conclude that the kidney has dual roles in aKlotho homeostasis, producing and releasing aKlotho into the circulation and clearing aKlotho from the blood into the urinary lumen.
aKlotho was originally identified as an anti-aging gene as its disruption confers a premature aginglike syndrome. 1 Overexpression of aKlotho reverses defects resulting from aKlotho deficiency and extends lifespan in mice. 1,2 aKlotho has extremely pleiotropic effects on multiple organs and is involved in many physiologic processes. 3, 4 Two other paralogs that share homology to aKlotho, are bKlotho, 5 and Klotho/lactase-phlorizin hydrolaserelated protein (Klph); also called gKlotho. 6 Both a-and b-Klotho function as co-receptors of different fibroblast growth factor (FGF) isoforms and serve distinct biologic actions. 4, [7] [8] [9] aKlotho is a type-I single-pass transmembrane protein with a long extracellular region harboring b-glucosidase-like motifs called Kl domains. 1, 5, 6, 10 aKlotho expression is restricted to a few organs including the kidney, 1 parathyroid glands, 11 and sinoatrial node 12 where it forms tetrameric complexes with FGFR1c, 3c, or 4 (2Klotho:2FGFR), and serves as the high-affinity receptor for circulating FGF23 to regulate mineral metabolism. 4, [13] [14] [15] bKlotho is expressed in the liver and fat and forms complexes with FGFR1c or 4 to support FGF15/19 and FGF21 signaling. bKlotho is involved in regulation of caloric homeostasis and bile secretion. 3, 16, 17 gKlotho is expressed in the skin and kidney, complexes with FGFR1b, 1c, 2c, or 4 in vitro but its physiologic function is not known. 4, 6 Of the three Klotho paralogs, aKlotho is the only one known to date to function both as a membrane-bound protein (co-receptor for FGF23) and a circulating endocrine substance. The extracellular portion of aKlotho is released from the cell by proteolytic cleavage 18, 19 and is present in the blood, 20, 21 urine, 21 and cerebrospinal fluid. 20 Theoretically, soluble aKlotho can form a complex with FGF and FGF receptor (FGFR) thus fulfilling its role as a co-receptor. However, as a soluble protein, it has much weaker action than transmembrane aKlotho thus seriously questioning whether soluble aKlotho can serve as a "deliverable co-receptor" for FGF23. 14, 15, 22 It is more likely that soluble aKlotho circulates to exert its effects independent of FGF23 and FGFR.
In the kidney, soluble aKlotho acts from the urinary luminal side as an autocrine or paracrine enzyme to regulate transporters and ion channels. aKlotho modifies the Na + -phosphate cotransporter NaPi-2a as a glucuronidase 21 and the renal outer medullary K + and TRPV5 calcium channel as a sialidase. 23, 24 In addition, aKlotho functions as a glucuronidase on the basolateral membrane modifying organic cation transport. 25 These enzymatic effects are clearly not due to aKlotho's function as a co-receptor for FGF23 and are FGF23-independent. The phosphaturic effect of injected soluble aKlotho is fully intact in the FGF23 2/2 mouse and in cultured cells in the complete absence of FGF23. 21 Further support of the endocrine action of circulating aKlotho is the fact that the systemic administration of recombinant Klotho protein 26, 27 or viral delivery of aKlotho 28 can rescue a multitude of the phenotypic features of genetic aKlotho deficiency in different organ systems. 26, 29 The kidney has the highest level of expression of aKlotho, but it is important to know whether aKlotho circulating in serum is derived from the kidney. Serum aKlotho levels in patients with CKD are extremely variable [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] probably due to assay-related variance. In contrast, renal aKlotho levels are uniformly reduced in CKD. 37, 40 Animal studies provide more consistent data supporting CKD as a state of global aKlotho deficiency, 10,41-43 which was recently confirmed in humans. 44 This finding supports but does not prove the model that the kidney is the source of endocrine aKlotho. The strongest evidence to date comes from renal tubule-specific partial deletion of aKlotho, which caused reduced serum aKlotho levels and systemic features closely resembling the phenotype in global aKlotho deletion mice; indicating that the kidney may be the principal source of endocrine aKlotho. 45 Even less studied than its source, the route of elimination of circulating aKlotho is completely unknown. There is no information on how this 130 kD protein is cleared from the circulation. We previously demonstrated the presence of intravenously injected exogenous extracellular domain of recombinant aKlotho protein in animal urine 42 but how aKlotho gets into the urine is not known.
The present study addresses several fundamental questions of aKlotho biology. Understanding the source and clearance of Klotho is critical because restoration of aKlotho in deficient states reverses the phenotype, 2, 26, 43 which has great therapeutic potential. 2, 26, 43 We show that the kidney is the principal contributor to circulating aKlotho and simultaneously, is also the major organ where circulating aKlotho is taken up from the circulation. Thus kidney disease is expected to affect both production and clearance of aKlotho in a complex fashion. Finally, circulating aKlotho is transported into the urine through transepithelial transcytosis, which provides an avenue for circulating aKlotho to function as luminal enzyme to modulate target proteins. These fundamental concepts are important for understanding the pathophysiologic mechanisms of aKlotho deficiency in kidney disease and any contemplation in replacement therapy.
RESULTS
The Kidney as a Source of Circulating aKlotho While aKlotho mRNA (RT-PCR, in situ hybridization, and RNA blot) is expressed in multiple tissues including heart, aorta, colon, pituitary gland, thyroid gland, pancreas, and gonads, the strongest expression by far is in the kidney. 1, 12, 21 aKlotho protein expression is detected in renal tubules, 21, 46 choroid plexus, 46 islet cells in pancreas, 47 and the parathyroid gland. 11, 48, 49 However, the high expression in the kidney does not necessarily indicate that circulating aKlotho is of renal origin. To test whether the kidney is a major source of endocrine aKlotho in mammals, we measured serum aKlotho protein in suprarenal and infrarenal vena cava of normal rats by direct puncture and human subjects who underwent right heart catheterization. All patients had eGFR$60 ml/min/1.73 m 2 . The medical conditions of the patients are shown in Supplementary  Table 1 . Similar infrarenal-to-suprarenal increment in caval aKlotho level was observed in both rat and human serum samples ( Figure 1, A and B) . We plotted serum aKlotho against serum erythropoietin, a well-known renal-derived hormone, and found that as serum erythropoietin rose ( Figure 1C) , and serum creatinine (S Cr ) decreased from infrarenal-to-suprarenal inferior vena cava (Supplementary Figure 1) , aKlotho increased indicating that the kidney secretes aKlotho into the circulation.
We next performed the classic organ ablation experiment to test the nephrogenic origin of aKlotho. When we removed both kidneys, serum aKlotho level dropped significantly to about half the normal level in one day. The fall in serum aKlotho parallels the rise in S Cr ( Figure 1D ) and BUN (Supplemental Figure 2 ). The anephric state did not permit studies to continue for longer than 40-50 hours.
Type-I transmembrane proteins can be cleaved and released by A disintegrin and metalloproteases (ADAM) which is a metalloprotease that functions as "sheddase" for membraneanchored growth factors, cytokines, and receptors. 50 ADAM plays an important role in modulation of cell signaling in physiology and pathophysiology. [50] [51] [52] Studies on cultured cell and kidney slices indicated that a-secretase (ADAM 10/ 17) and b-secretase modulate aKlotho ectodomain shedding and becoming soluble aKlotho protein, 18, 19 by acting on two cleavage sites: one close to the juxtamembrane region (aa 950 approximately981) and another between the KL1 and KL2 domains. 53 To examine if secretases modulate circulating aKlotho in vivo, we injected a-secretase inhibitor doxycline hyclate and/or b-secretase inhibitor III into the intraperitoneal cavity of normal mice for 2 days and determined serum aKlotho in 48 hours. Serum aKlotho levels were decreased with either one or both a-and b-secretase inhibitors ( Figure  1E ) supporting the notion that aKlotho release depended on secretases.
The Kidney as a Portal of Clearance of Circulating aKlotho from Blood It is not known how aKlotho is cleared from the circulation. To examine this, we injected fluorescent exogenous recombinant aKlotho protein into the intraperitoneal cavity of normal and anephric rats. The levels of circulating exogenous aKlotho Upper panel shows immunoblot of aKlotho proteins immunoprecipitated with anti-aKlotho antibody from 0.1 ml serum from infrarenal and suprarenal IVC from three subjects. Bottom panel is a summary from nine patients and significant difference between infrarenal and suprarenal IVC was assessed by paired t test, and significant differences were accepted when **P,0.01. (C) Serum aKlotho levels (y axis) were plotted against serum erythropoietin (EPO) levels (x axis) measured in the same sample. The infrarenal and suprarenal samples from the same individuals are connected by lines. (D) Change in endogenous serum aKlotho in anephric rats subjected to bilateral nephrectomy (Npx). Blood was drawn at the specified time points post-surgery. Serum aKlotho was determined by immunoprecipitation-immunoblot. Upper panel is a representative blot. Bottom panel is a summary of serum aKlotho and serum Cr from three independent experiments. Data are expressed as means6SD. Statistical significance was assessed by one-way ANOVA followed by Student-Newman-Keuls test, and significant differences were accepted when *P,0.05; **P,0.01* versus hour 0. (E) WT mice were injected intraperitoneally with a-or/ and b-secretase inhibitors (a-Inh, b-Inh) for 2 days and serum aKlotho was determined by immunoprecipitation-immunoblot. Upper panel is one set of representative data. Bottom panel is a summary of arbitrary unit of serum aKlotho over IgG HC from three independent experiments. Statistical significance was assessed by one-way ANOVA followed by post hoc Student-Newman-Keuls test, and was considered significant when *P,0.05 or **P,0.01 versus vehicle (DMSO); # P,0.05 versus a-secretase inhibitor.
protein in anephric rats were similar to those in normal rats immediately after injection (Figure 2A ), but the half-life of exogenous aKlotho protein in normal rats was much shorter than that in anephric rats ( Figure 2 , B) and the half-life of endogenous aKlotho upon nephrectomy closely approximates that of exogenous aKlotho in the anephric rats ( Figure  2B , gray and black closed circles).
Distribution of Exogenous aKlotho Protein in Rodent Organs
The lengthening of the half-life of exogenous aKlotho with nephrectomy implies that the kidney may be clearing aKlotho. Alternatively, the anephric state can alter aKlotho clearance by other organs. To distinguish these possibilities, we examined the anatomic fate of exogenous labeled aKlotho protein in the kidney. After an intravenous injection of 125 Ilabeled aKlotho protein ( 125 I-aKlotho) into normal rats, we found that the kidney is a major organ for exogenous aKlotho protein uptake, with much lower signals in other organs (Figure 3A) . The signal of the 125 I-albumin control is unquestionably different from that of 125 I-labeled aKlotho ( Figure 3A ), indicating that the signal of aKlotho in the kidney is not just due to trapping of aKlotho in renal vascular beds. Quantitative scintillation counting in tissue homogenates showed high signal of 125 I-labeled aKlotho in the kidney and in urine compared with that in the blood ( Figure 3B ), supporting that the kidney may be a major organ of aKlotho uptake as well as its excretion.
We found a high signal in the renal medulla and papilla immediately after injection of 125 I-aKlotho, which diminished by 30 min and disappeared by 120 min ( Figure 3C ). This signal likely came from free 125 I released from 125 I-aKlotho which we detected (data not shown) and is largely unavoidable. To independently confirm the high signal in the kidney, we covalently labeled recombinant aKlotho with infrared dye 42 and examined aKlotho distribution in several organs in normal rats. Similar to the radioactive labeling, exogenous infrared labeled aKlotho protein was prominently distributed in the kidney and spleen, sparsely in the heart ( Figure 3D ), and not detectable in aorta, brain, and muscle (data not shown).
To characterize the clearance profile of aKlotho from the circulation into urine, we intravenously injected 125 I-aKlotho into normal rats and simultaneously measured the radioactivity in the urine and serum over 2 hours. The serum aKlotho signal quickly decreased by half over approximately 4 min (due to redistribution) followed by a slower steady decline (Supplemental Figure 3A) . The 125 I-aKlotho clearance pattern was clearly different from that of 125 I-albumin, which was mainly retained in the circulation (Supplemental Figure  3B) . As serum 125 I-aKlotho radioactivity decreased, urinary radioactivity rose simultaneously (Supplemental Figure 3C) . In comparison, radioactivity of albumin in the urine remained low (Supplemental Figure 3D) . These findings support the notion that aKlotho protein is cleared from blood through the kidney into the urine.
Distribution of Exogenous aKlotho Protein in the Kidney
As discussed previously, upon injection of 125 I-aKlotho to rats, autoradiography showed that the signal in the renal cortex appeared first and gradually increased followed by a signal in the inner medulla later. The signal in the cortical rim persisted up to 120 minutes ( Figure 3C ). The infrared (IR) labeled aKlotho imaging clearly demonstrates that exogenous aKlotho was not in glomeruli but exclusively present in renal tubules in the cortex and the outer strip of the medulla ( Figure 4A ).
To further localize the segment of renal tubules in the cortex where exogenous aKlotho is taken up, we intravenously injected doubled-labeled fluorescent aKlotho into normal mice. There was no detectable signal of labeled IgG in the kidney (negative control, data not shown), whereas a clear aKlotho signal is present in the cortex starting 2 minutes after injection and a stronger signal was observed in 30 minutes. LabeledaKlotho was present in both proximal and distal tubules (Figure 4B) but not in the glomeruli (not shown).
To delineate the locale of exogenous aKlotho further, we injected recombinant extracellular domain of mouse aKlotho into homozygous aKlotho hypomorphic (kl/kl) mice. 1 As expected, immunoelectron microscopy (EM) did not detect endogenous aKlotho protein in the kidney of kl/kl mice (data not shown). Exogenous aKlotho was clearly found inside the glomerular capillary, the glomerular basement membrane (GBM), but not in Bowman's space despite extensive search over many images from many glomeruli ( Figure 4C ). However, exogenous aKlotho was present in the lumen, apical and basolateral membranes, and cytoplasm in both distal and proximal tubules, and in peri-tubular capillary lumen ( Figure  4 , D-F, Supplemental Figure 4) .
High radioactive counts were present both in the serum and urine (Supplemental Figure 3 , A and C). To exclude the possibility that radioactivity in urine and serum was merely free 125 I released from 125 I-aKlotho, we resolved the urine proteins by SDS-PAGE followed by autoradiography. There was indeed some free 125 I that ran off the gel (data not shown) but full-length aKlotho was clearly detectable in urine ( Figure 5A ). Small amounts of albumin were also detected in urine but very limited ( Figure 5B) .
The fact that aKlotho is not filtered may be intuitively expected for a 130 kDa protein. Since aKlotho functions as an enzyme, 13, 21, 54 it can theoretically modify the glycans and hence reduce the negative charge barrier of the GBM with resultant leak of aKlotho into urine. To exclude that, we treated fresh normal kidney slices with aKlotho, glucuronidase, or sialidase, and examined their effects on negative charge. aKlotho did not affect glomerular negative charge rendering glomerular leak unlikely (Supplemental Figure 5) .
To further explore how aKlotho gets into the urine, we measured radioactivity in the proximal lumen urine using free-flow micropuncture. 21 Radioactivity was highest in the urine but undetectable in Bowman's space ( Figure 5C ), which is consistent with immunoelectron micrographs ( Figure 4C ) showing no visible aKlotho antigen in Bowman's space.
125
I-aKlotho was detected in high quantity in the lumen which is remarkably different from that of the control protein 125 I-albumin ( Figures 3B and 5C ). In light of the fact that injected IR-labeled full length aKlotho is present in urine, 42 we conclude that exogenous aKlotho protein is cleared from blood by the kidney and excreted into urine at the level of the renal tubule. We do not exclude other possibilities such as hepatic and splenic clearance as exogenous aKlotho was also found in the liver and spleen ( Figure 3A) .
Transcytosis of aKlotho by Renal Proximal Tubules
The absence and presence of aKlotho in Bowman's space and proximal lumen, respectively, suggests that aKlotho traffics across renal tubules from basolateral membrane to luminal membrane. We next used OK cells, an opossum kidney cell line with renal proximal tubular features 55 as an in vitro model 125 I-labeled aKlotho protein was intravenously injected into normal rats and kidneys were harvested at specific time points and cryosections were made for autoradiography. (D) Infrared-labeled aKlotho was intraperitoneally injected into normal rats. Two hours later, kidney, spleen, and heart were harvested, sectioned, and scanned with IR imager system.
to examine aKlotho transcytosis. aKlotho was taken up by OK cells from both apical and basal media, but only aKlotho internalized from the basal side was secreted into apical media ( Figure 6A ); internalized aKlotho from apical media was not released into basal media ( Figure 6B ) suggesting unidirectional trafficking. There was no transcytosis of albumin or IgG across OK cells either from basal to apical or from apical to basal side (data not shown). Taken together with the dot blot data shown in Figure 6C , one can say that aKlotho is taken up by OK cells from the basal side, then crosses the cell to the apical side which occurs as early as 30 minutes and plateaus by 8 hours.
DISCUSSION
The main findings in this study are: (1) the kidney produces and releases soluble aKlotho into the systemic circulation by secretases-mediated shedding of the ectodomain of aKlotho, (2) the kidney is an important organ to clear soluble aKlotho from the circulation, (3) aKlotho traffics across renal tubules from basolateral to intracellular location and is then secreted across the apical membrane into the urinary lumen. aKlotho is found in urine and serum of rodents and humans 2, 20, 42, 56 ; and the kidney has the highest abundance of aKlotho compared with other organs. Clinical and experimental animal studies showed low renal tubular aKlotho expression in both acute kidney injury and CKD 10, 40, 42, 43, [56] [57] [58] [59] [60] [61] [62] and low circulating aKlotho levels in kidney diseases of a variety of etiologies in animals 42, 43, 56, 62 and humans. 32, 44, 61, 63 These data suggest that the kidney contributes to circulating aKlotho. Now we provide direct experimental evidence that the kidney is the source of circulating aKlotho by demonstrating step-up of aKlotho concentration from infrarenal to suprarenal vena cava in both mice and humans. Further evidence for a renal source of circulating aKlotho is that serum aKlotho falls rapidly aKlotho labeled with two types of fluorescent dye: Alexa 555 C2 Maleimide (l ex 555 nm, l em 565 nm) and TAMRA-SE (l ex 546 nm, l ex 579 nm) was intravenously injected into normal rats, and kidneys were collected at specific time points and subjected to immunofluorescent staining for aKlotho, NaCl cotransporter (NCC), and Lotus-Tetragonolobus lectins (LTA). Asterisks depict glomerulus. DCT: distal convoluted tubule; IM: inner medulla; IS: inner strip of outer medulla; PCT: proximal convoluted tubule. (C-F). aKlotho protein was intraperitoneally injected into homozygous aKlotho-deficient mice and the kidneys were harvested for immunogold electron microscopy. Representative electron micrographs of exogenous aKlotho in (C) glomeruli, (D, E) proximal tubules, (F) distal tubules. Arrows indicate gold particle (labeled aKlotho protein).
upon bilateral nephrectomy although one cannot rule out the possibility that the acute anephric state has suppressive effect on extrarenal source of aKlotho. We cannot extend our bilateral nephrectomy experiment beyond 2-3 days to test whether circulating aKlotho levels disappear entirely. Both proximal convoluted tubules and distal convoluted tubules express aKlotho protein and transcripts, 21 but we do not know whether both segments release aKlotho into the circulation. It is unclear whether other organs contribute to circulating soluble aKlotho in physiologic 11, 12, 45, 48, 64 or pathologic states. 65 Lindberg and colleagues generated a conditional partial aKlotho deletion in renal tubules 45 with a similar phenotype as global aKlotho deletion. In addition, serum aKlotho level was reduced by approximately 80% compared with wild-type and aKlotho shedding from kidney explants was undetectable, 45 suggesting that kidney is a principal contributor of circulating aKlotho.
A second role of the kidney in aKlotho homeostasis is clearance from the circulation. The kidney likely serves to remove aKlotho, and acts as a conduit to deliver it to the tubular lumen. Endogenous aKlotho protein is still present in the circulation 2 days after nephrectomy. The post-nephrectomy endogenous aKlotho half-life approaches that of exogenous aKlotho in the anephric state (Figure 2) , indicating that the kidney is a major organ to clear circulating aKlotho. In CKD vitamin D receptor agonist increased serum and urine aKlotho levels, but did not increase aKlotho expression in kidney, aorta, brain, and parathyroid. 65 In the absence of kidneys, one does not know which are the predominant organs of production and clearance. Extra-renal aKlotho production might be low or undetectable under normal aKlotho status and in acute loss of renal function, but could possibly be stimulated in chronic aKlotho deficiency akin to increased hepatic production of erythropoietin in renal failure. 66 The renal actions of aKlotho include, but are not limited to, suppression of NaPi activity in proximal, 21 inhibition of renal outer medullary K + in the thick ascending limb and the cortical collecting duct, 24 stimulation of TRPV5 in renal distal tubules, 23, 67, 68 and protection of kidney from oxidative injury. 42, [57] [58] [59] 69, 70 To exert its action on transporters, entrance to the tubular lumen is a prerequisite. We definitively show that exogenously administered aKlotho protein is present in proximal and distal tubular lumen (Figures 4 and 5) , which can explain the effect on tubular transport with aKlotho injection. 21, 24 Soluble aKlotho protein is the extracellular domain of membrane Klotho (approximately 130 kDa) [18] [19] [20] which is not filtered across the glomerular barrier. 71 Furthermore, we did not see decreased negative charge in the GBM when kidney sections were directly incubated with aKlotho (Supplemental Figure 5 ) and in vivo studies did not show increased urinary protein excretion in normal rats acutely perfused with aKlotho and Tg-Kl mice with chronic higher levels of aKlotho. 21, 43 Free-flow micropuncture from Bowman's space showed low radioactivity after injection with 125 I-aKlotho ( Figure 5C ). Thus, the exogenous aKlotho that ends up in the urine is tubular in origin probably through transcytosis across proximal renal tubules. This was further tested by adding aKlotho to the basolateral media of OK cells and confirmed by the presence of aKlotho in the apical media ( Figure  6 ). In contrast, there is no traffic of aKlotho from apical media to basolateral media. Transcytosis may serve as a way to clear circulating aKlotho, or as a mean to channel aKlotho to the lumen to modulate transporters or channels on the apical membrane of renal tubules. Two points are noteworthy. Firstly, both proximal and distal tubules take up circulating aKlotho ( Figure 4B ) but we cannot discern at present the relative contribution of each of these segments to trans-tubular aKlotho transport. Secondly, aKlotho in the urine can be hematogenously derived via transcytosis but it can also originate from the renal tubules as well. Currently, we do not know the relative contribution from circulation versus renal tubules; and from proximal tubules versus distal tubules to urinary aKlotho.
In conclusion, the kidney is the principal organ in the maintenance of aKlotho homeostasis by contributing to circulating aKlotho. The clearance of circulating aKlotho is also partially mediated by the kidney. Hematogenously derived aKlotho is present in renal tubular lumen which is a key site of physiologic action of aKlotho. Therefore, the kidney assumes several functions in aKlotho homeostasis: contribution to systemic endocrine aKlotho, clearance of circulating aKlotho, and delivery of aKlotho to the tubular lumen. With the renal source of circulating aKlotho established, the next step would be to delineate why and how aKlotho is drastically reduced with both acute and CKD which is of immense clinical significance. In addition, establishing extrarenal sources of aKlotho and testing whether there is upregulation of aKlotho production from extrarenal sources when renal production fails will also be of paramount importance. 
CONCISE METHODS

Human Studies
Nine human subjects (49.066.2 years) who underwent right heart catheterization were enrolled for this study (Supplementary Table 1) , which was approved by the Institutional Review Board at the University of Texas Southwestern Medical Center, and all subjects gave informed consent. During right heart catheterization, suprarenal and infrarenal vena caval blood samples were obtained and sera were immediately separated after centrifugation at 4°C and stored at 280°C for future study. Serum aKlotho was determined by immunoprecipitation-immunoblot assay described previously. 21, 42, 63 Briefly, 0.1 ml serum was immunoprecipitated with a synthetic anti-aKlotho Fab (sb106) 63 and immune complex was eluted with Laemmli sample buffer, and subject to immunoblot with KM2076 antibody. 21, 42, 63 The specific signals on the autoradiograms based on 130 kD mobility were quantified with ImageJ Program (National Institutes of Health (NIH), Bethesda, Maryland).
Animal Studies
aKlotho hypomorphic (kl/kl) mice were described previously. 1 kl/kl mice and their wild-type (WT) littermates were maintained at the Animal Research Center at the University of Texas Southwestern Medical Center. Currently all mice are 129 S1/SVlmJ (129 SV) background age from 6 to 8 weeks. Normal Sprague-Dawley (SD) rats (220-250 g body weight) were purchased from Charles River Laboratories (Wilmington, MA). For aKlotho clearance study, rats underwent bilateral nephrectomy (anephric rats) or laparotomy with manual manipulation of the kidneys (sham rats). Rats or mice were intravenously or intraperitoneally injected once with labeled full extracellular domain of recombinant mouse aKlotho protein (rMKl) (R&D Systems, Minneapolis, MN) at a dose of 0.1 mg/kg body weight.
To examine if secretases modulate blood aKlotho, doxycline hyclate (Sigma-Aldrich, St. Louis, MO), an a-secretase inhibitor at 25 mg/kg/day, and/or b-secretase inhibitor III (Calbiochem, Billerica, MA) at 2.5 mg/kg/day were intraperitoneally injected into normal WT mice daily for 2 days, blood and kidneys were harvested at 48 hours to determine serum and renal aKlotho. All animal studies were approved by the Institutional Animal Care and Use Committee at the University of Texas Southwestern Medical Center, Dallas, TX.
Antibodies and Other Key Reagents
Rat monoclonal anti-human Klotho antibody, KM2076 1,2 was used for immunoblotting and immunoelectron microscopy; and the synthetic anti-aKlotho antibody sb106 63 was used for immunoprecipitation of serum Klotho. Anti-His antibody was purchased from Invitrogen (Carlsbad, CA), NaCl cotransporter (NCC) from Chemicon, (EMD Millipore, Billerica, MA), Lotus-Tetragonolobus lectins (LTA) from Vector laboratories (Burlingame, CA), and other chemicals were obtained from Sigma-Aldrich, except otherwise noted. Culture media were purchased from Invitrogen; penicillin and streptomycin from Cambrex (East Rutherford, NJ); infrared dye 800 CW from LI-COR Biosciences (Lincoln, NE), carboxy-tetramethylrhodamine succinimidyl ester from G-Biosciences (St. Louis, MO); Figure 6 . aKlotho transcytosis from basal to apical side in OK cells. OK cells were seeded on Transwell plates and grown to confluence to separate apical and basolateral side. (A) aKlotho with C-terminal 6His tag was added to the basal medium. At given time points after incubation, media were collected from both apical and basal side, and subjected to immunoblot to quantify exogenous aKlotho protein with anti-His antibody (left panel). Right panel is a summary of total amount of aKlotho at each time point in each compartment. Data are expressed as means6SD from three independent experiments. Statistical significance was assessed by one-way ANOVA followed by StudentNewman-Keuls test, and significant differences were accepted when *P,0.05 versus 0 min. (B) aKlotho with C-terminal 6His tag was added to the apical medium. At given time points after incubation, media were collected from apical and basal side and subjected to immunoblot for quantitation of aKlotho protein with anti-His antibody (left panel). Right panel is a summary of total amount of aKlotho at each time point in each compartment. Data are expressed as means6SD from three independent experiments. Statistical significance was assessed by one-way ANOVA followed by Student-Newman-Keuls test. None of the changes were statistically significant. (C). Time course of transcytosis. Media were collected from the apical side when aKlotho with Cterminal 6His tag was added to the basal side, and subjected to dot blot aKlotho protein with anti-His antibody (upper panel 
Clearance of Labeled aKlotho in Rats and Mice
Normal Munich Wistar rats (220-250 g BW) were anesthetized with Inactin (100 mg/kg BW), and a bonus of labeled aKlotho was injected through the jugular vein (0.1 mg/kg BW). For the experiment of injection of 125 I-labeled aKlotho or 125 I-labeled albumin, fluid collection by free-flow micropuncture of Bowman's space, and proximal convoluted tubules was performed using our published methods. 21 In brief, the left kidney was exposed, and the left ureter was catheterized for urine collection. Proximal tubules were identified by their characteristic configuration after lissamine green dye injection and punctured with glass capillaries. The volume of fluid was measured in a calibrated constant-bore glass capillary. The radioactivity of fluids was determined by scintillation accounting and normalized to fluid volume. At specified time points, blood was drawn from retro-orbital venous sinus, and spot urine was collected. 125 I-labeled aKlotho or 125 I-labeled albumin in collected urine and serum was quantified by scintillation counting. Homogenates of different organs were made and radioactivity in organ homogenates was measured by scintillation counting, and normalized to protein in organ homogenates. Organ sections (10 mm) were subjected to autoradiography.
Distribution and Location of Labeled aKlotho in the Kidney
For the experiment of injection of IR-labeled aKlotho, normal SD rats were used. Four ml of serum or fresh spot urine were solubilized in Laemmli sample buffer, fractionated by 7.5% SDS-PAGE, and scanned with Odyssey Infrared Imaging System (LI-COR Biosciences). Kidneys were snap-frozen in liquid N 2 and stored in 280°C. Four mm cryosections were made and scanned directly without fixation using Odyssey Infrared Imaging System or Stormä 860 imager (GE Healthcare). For the experiment of injection of fluorescent labeled aKlotho, kidney sections were imaged by immunofluorescent microscopy, and immunohistologically stained with aKlotho, NaCl cotransporter (NCC), and Lotus tetragonolobus lectins (LTA).
Opossum Kidney (OK) Cells
OK cells were cultured and maintained in high-glucose (450 mg/dl) Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 g/ml) as described. 21 For transcytosis study, OK cells were seeded on Transwell, and grown to complete confluence for 2 days (typical transepithelial resistance approximately 1-5 kV). 72 For uptake study, fluorescein-labeled aKlotho protein with C-terminal 6His tag was added into either apical or basal compartment and incubated for 4 hours. Apical or basal media was then collected for immunoblot for aKlotho with anti-His antibody. For determination of radioactivity, 10 ml of media from different compartments and cell lysate was subject to scintillation counting and also subjected to SDS-PAGL followed by autoradiography.
Immunoblot
Immunoblotting was performed as described. 21, 42 Briefly, total lysates were extracted from kidney tissues and OK cells in radioimmunoprecipitation (RIPA) buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 1% Triton X-100, 0.5% deoxycholate, and 0.1% SDS) containing fresh phosphatase inhibitors and protease inhibitors. Protein content in samples was determined by the method of Bradford. 21, 42 Thirty mg of protein were fractionated by SDS-PAGE, and electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes. After blocking in nonfat milk, membranes were probed with anti-Klotho monoclonal antibody (KM2076) 42 (overnight 4°C) and followed by secondary antibodies conjugated with horseradish peroxidase (GE Healthcare). Antibody against b-actin (Sigma-Aldrich) was used for loading control. Signal was visualized by enhanced chemiluminescence (GE Healthcare), and quantified densitometrically by the Scion/NIH ImageJ software (Scion, Frederick, MD). For assay of serum aKlotho, 100 ml of serum from rodents was subjected to immunoprecipitated enrichment by sb106 aKlotho 44 and was immunoblotted by rat anti-human aKlotho (KM2076).
Immunoelectron Microscopy
Mouse recombinant Klotho protein (0.1 mg/kg BW) was intraperitoneally injected once into kl/kl mice and mice were sacrificed 24 hours after injection. Kidneys were harvested and fixed with 2.5% paraformaldehyde via aortic perfusion, removed, and post-fixed in 4% paraformaldehyde (4°C for 4 hours). Immunogold labeling of ultrathin frozen tissue sections was performed as described. 21 Kidney cortex was infiltrated with 2.3 M sucrose overnight, frozen in liquid nitrogen, and 70-80-nm-thick sections were made (Ultramicrotome Reichert Ultracut E; Leica Microsystems, Wetzlar, Germany) and mounted on Formvar-coated nickel grids. The sections were incubated with KM2076 antibody and followed by incubation with gold-conjugated protein A (10-nm gold particles, Sigma-Aldrich) for 60 minutes. After staining with uranyl acetate, sections were visualized with Jeol 1200 EX transmission electron microscope (Jeol Ltd., Akishima, Japan).
Statistical Analyses
Data are expressed as the means6SD. Statistical analysis was performed using unpaired t test, or paired t test, or ANOVA followed by Student-Newman-Keuls test whenever appropriate. A P-value of#0.05 was considered statistically significant. Unless otherwise stated, representative figures reflect the results in a minimum of three independent experiments.
